2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2268

Patient-Reported Outcome Measures For Rheumatoid Arthritis: Minimal Important Differences Review
Abstract Number: 1546

Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 1528

Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity
Abstract Number: 1543

Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia
Abstract Number: 1529

Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Abstract Number: 114

Patients With Regular Physical Activity Before Onset Of Rheumatoid Arthritis Present With Milder Disease
Abstract Number: 717

Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th17 Responses But Preserved Oral Candida Albicans Protective Immunity
Abstract Number: 1682

Patients With TAKAYASU’S Arteritis Having Persistent ACUTE PHASE Response Usually Have An Increased MAJOR Vessel Uptake By 18F-FDG-PET/CT
Abstract Number: 2246

Patients’ Assessment of the Disease Greatly Influences the Determination of Disease Activity and Remission in Rheumatoid Arthritis
Abstract Number: 2543

Patients’ Perception Of Their Lupus Disease Activity, But Not Overall Health, Correlates With Physician Assessments
Abstract Number: 1930

Patients’ Response To a Sleep Question and Disease Activity In Multiple Rheumatic Conditions
Abstract Number: 530

Pattern Recognition Receptor Stimulated Cytokine Expression By Spondyloarthritis Patient Macrophages
Abstract Number: 437

Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Abstract Number: 1648

PD-1⁺CD45RB^lo122^lo Autoantibody-Inducing CD4 T Cells (aiCD4 T cells) As a Key In The Pathogenesis Of Systemic Lupus Erythematosus (SLE)
Abstract Number: 2792

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].